Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
pubmed:
8
9
2023
medline:
8
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Sinonasal myxomas are rare benign tumors of the maxillary bone and sinus. There is published evidence that sinonasal myxomas occurring in children up to 3 years of age ("infantile sinonasal myxomas") are clinically distinctive and harbor Wnt signaling pathway alterations. Here, we characterized 16 infantile sinonasal myxomas and compared them to 19 maxillary myxomas and 11 mandibular myxomas in older patients. Clinical follow-up was available for 21 patients (46%) overall (median: 2.6 y; range: 4 mo to 21 y), including 10 of 16 infantile sinonasal myxomas (62%). None of the 8 resected infantile sinonasal myxomas recurred, despite positive margins in 6 of them. One incompletely resected infantile sinonasal myxoma underwent partial regression without additional treatment. In contrast, 4 of the 11 other myxomas with follow-up recurred (36%), including one that recurred twice. Imaging studies demonstrated all infantile sinonasal myxomas to be expansile lesions arising from the anterior maxillary bone adjacent to the nasal aperture, with peripheral reactive bone formation. Histologically, infantile sinonasal myxomas showed short, intersecting fascicles of bland fibroblastic cells with prominent stromal vessels. Examples with collagenous stroma showed some morphologic overlap with desmoid fibromatosis, although none showed infiltrative growth into adjacent soft tissue. Immunohistochemistry demonstrated nuclear β-catenin expression in 14 of 15 infantile sinonasal myxomas (93%), in contrast to 4 of 26 other myxomas of craniofacial bones (15%). Smooth muscle actin was expressed in only 1 of 11 infantile sinonasal myxomas (9%). Next-generation sequencing was successfully performed on 10 infantile sinonasal myxomas and 7 other myxomas. Infantile sinonasal myxomas harbored CTNNB1 point mutations in 4 cases (D32Y, G34E, G34R, and I35S), and none harbored alterations to the phosphorylation sites T41 and S45 that are altered in 99% of CTNNB1 -mutant desmoid fibromatoses. Three tumors showed alterations consistent with biallelic APC inactivation. Three infantile sinonasal myxomas that showed strong nuclear β-catenin expression were negative for CTNNB1 and APC alterations. Sequencing was negative for CTNNB1 or APC alterations in all 7 myxomas of craniofacial bones in older patients. Four of these myxomas in older patients (57%) showed copy number alterations, and all lacked known driving alterations. These findings support the notion that infantile sinonasal myxomas are clinically and genetically distinctive, and we propose the use of the diagnostic term "infantile sinonasal myxoma" to distinguish this tumor type from other myxomas of the craniofacial bones. Infantile sinonasal myxoma should be distinguished from desmoid fibromatosis because of its unique clinical presentation, more indolent clinical behavior, different morphology, different immunohistochemical profile, and different genetics. Given its indolent behavior even when marginally excised, infantile sinonasal myxoma can be managed with conservative surgery.
Identifiants
pubmed: 37678343
doi: 10.1097/PAS.0000000000002119
pii: 00000478-990000000-00226
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1301-1315Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Safadi A, Fliss DM, Issakov J, et al. Infantile sinonasal myxoma: a unique variant of maxillofacial myxoma. J Oral Maxillofac Surg. 2011;69:553–558.
Mewar P, González-Torres KE, Jacks TM, et al. Sinonasal myxoma: a distinct lesion of infants. Head Neck Pathol. 2020;14:212–219.
Muzio LL, Nocini P, Favia G, et al. Odontogenic myxoma of the jaws: a clinical, radiologic, immunohistochemical, and ultrastructural study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82:426–433.
Dotta JH, Miotto LN, Spin‐Neto R, et al. Odontogenic myxoma: systematic review and bias analysis. Eur J Clin Invest. 2020;50:e13214.
Martins H, Vieira E, Gondim A, et al. Odontogenic myxoma: follow-up of 13 cases after conservative surgical treatment and review of the literature. J Clin Exp Dent. 2021:e637–e641.
Mullen JT, DeLaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19:4028–4035.
Soto-Miranda MA, Sandoval JA, Rao B, et al. Surgical treatment of pediatric desmoid tumors. a 12-year, single-center experience. Ann Surg Oncol. 2013;20:3384–3390.
Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159:450–453.
Flucke U, Tops BBJ, van Diest PJ, et al. Desmoid-type fibromatosis of the head and neck region in the paediatric population: a clinicopathological and genetic study of seven cases. Histopathology. 2014;64:769–776.
Daram SP, Timmons C, Mitchell RB, et al. Desmoid fibromatosis of the maxilla. Ear Nose Throat J. 2020;99:NP6–NP8.
Ahmed AA, Vundamati D, Farooqi M, et al. Next-generation sequencing in the diagnosis of rare pediatric sinonasal tumors. Ear Nose Throat J. 2021;100:NP263–NP268.
Velez Torres JM, Mata DA, Briski LM, et al. Sinonasal myxoma: a distinct entity or a myxoid variant of desmoid fibromatosis? Mod Pathol. 2023;36:100189.
Prasannan L, Warren L, Herzog CE, et al. Sinonasal myxoma: a pediatric case. J Pediatr Hematol Oncol. 2005;27:90–92.
Garcia EP, Minkovsky A, Jia Y, et al. Validation of oncopanel a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med. 2017;141:751–758.
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–443.
Kadlub N, Mbou VB, Leboulanger N, et al. Infant odontogenic myxoma: a specific entity. J Craniomaxillofac Surg. 2014;42:2082–2086.
Boson WL, Gomez RS, Araujo L, et al. Odontogenic myxomas are not associated with activating mutations of the Gs alpha gene. Anticancer Res. 1998;18:4415–4417.
Friedrich RE, Scheuer HA, Assaf AT, et al. Odontogenic myxomas are not associated with GNAS1 mutations. Anticancer Res. 2012;32:2169–2172.
Siqueira EC, Sousa SF, Carlos R, et al. Odontogenic myxomas lack PDGFRB mutations reported in myofibromas. J Oral Pathol Med. 2020;49:278–283.
Perdigão PF, Stergiopoulos SG, De Marco L, et al. Molecular and immunohistochemical investigation of protein kinase a regulatory subunit type 1A (PRKAR1A) in odontogenic myxomas. Genes Chromosomes Cancer. 2005;44:204–211.
Best-Rocha A, Patel K, Hicks J, et al. Novel association of odontogenic myxoma with constitutional chromosomal 1q21 microduplication: case report and review of the literature. Pediatr Dev Pathol. 2016;19:139–145.
Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, et al. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. Am J Dermatopathol. 2006;28:105–111.
Ujifuku K, Sadakata E, Baba S, et al. Primary intracranial aggressive fibromatosis arising in sella turcica: illustrative case. J Neurosurg Case Lessons. 2021;2:CASE21396.
Moore D, Burns L, Creavin B, et al. Surgical management of abdominal desmoids: a systematic review and meta-analysis. Ir J Med Sci. 2023;192:549–560.
Chan EF, Gat U, McNiff JM, et al. A common human skin tumour is caused by activating mutations in β-catenin. Nat Genet. 1999;21:410–413.
Miyoshi Y, Iwao K, Nawa G, et al. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res. 1998;10:591–594.
Laskin WB, Lasota JP, Fetsch JF, et al. Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases. Am J Surg Pathol. 2015;39:197–205.
Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997;275:1787–1790.
Coste A, de L, Romagnolo B, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95:8847–8851.
Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998;58:3526–3528.
Tissier F, Cavard C, Groussin L, et al. Mutations of β-caten in in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622–7627.
Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science. 1996;272:1023–1026.
Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem. 1997;272:24735–24738.
Behrens J, Jerchow B-A, Würtele M, et al. Functional interaction of an axin homolog, conductin, with β-catenin, APC, and GSK3β. Science. 1998;280:596–599.
Provost E, Yamamoto Y, Lizardi I, et al. Functional correlates of mutations in β-catenin exon 3 phosphorylation sites. J Biol Chem. 2003;278:31781–31789.
Provost E, McCabe A, Stern J, et al. Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene. 2005;24:2667–2676.
Aitken SJ, Presneau N, Kalimuthu S, et al. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch. 2015;467:203–210.
Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis: genomic analysis of wild-type desmoids. Genes Chromosomes Cancer. 2015;54:606–615.
Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6614–6620.
Abraham SC, Reynolds C, Lee J-H, et al. Fibromatosis of the breast and mutations involving the APC/β-catenin pathway. Hum Pathol. 2002;33:39–46.
Lazar AJF, Tuvin D, Hajibashi S, et al. Specific mutations in the β-Catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–1527.
Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49:560–568.
Colombo C, Bolshakov S, Hajibashi S, et al. ‘Difficult to diagnose’ desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology. 2011;59:336–340.
Bo N, Wang D, Wu B, et al. Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Dev Pathol. 2012;15:173–178.
Le Guellec S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012;25:1551–1558.
Wang W-L, Nero C, Pappo A, et al. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. Pediatr Dev Pathol. 2012;15:361–367.
Koike H, Nishida Y, Kohno K, et al. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study. Hum Pathol. 2019;84:155–163.
Norkowski E, Masliah-Planchon J, Le Guellec S, et al. Lower rate of CTNNB1 mutations and higher rate of APC mutations in desmoid fibromatosis of the breast: a series of 134 tumors. Am J Surg Pathol. 2020;44:1266–1273.
Sholl LM, Do K, Shivdasani P, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016;1:e87062.